Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo

• Autores principales: Marion Anliker‐Ort (Autor), Jasper Dingemanse (Autor), Stephane Delahaye (Autor), Luboš Janů (Autor), John van denAnker (Autor), Benjamin Berger (Autor), Priska Kaufmann (Autor)
• Formato: Libro
• Publicado: Wiley, 2023-07-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract ACT‐1014‐6470 is an orally available complement factor 5a receptor 1 antagonist and a novel treatment option in auto‐inflammatory diseases. The in vitro inhibition potential of ACT‐1014‐6470 on cytochrome P450 isozymes (CYPs) and its effect on the pharmacokinetics (PK) of the CYP2C19 and CY...